This PON1 deficiency reflects in a weaker anti-atherogenic action, with HDL from T2D patients being less effective in counteracting the inhibitory effect of oxidized LDL on vasorelaxation [44] and endothelial nitric oxide synthesis [45]. This evidence concerns the gene PON1 and type 2 diabetes mellitus.